View ValuationSamjin Pharmaceuticals 향후 성장Future 기준 점검 0/6Samjin Pharmaceuticals의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Pharmaceuticals 이익 성장23.8%매출 성장률3.1%향후 자기자본이익률6.40%애널리스트 커버리지Low마지막 업데이트21 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jul 29Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.4% to ₩16,960. The fair value is estimated to be ₩21,389, however this is not to be taken as a buy recommendation but rather should be used as a guide only.공고 • Jun 12An undisclosed buyer acquired 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) for KRW 23.4 billion.An undisclosed buyer agreed to acquire 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) for KRW 23.4 billion on May 14, 2026. A cash consideration of KRW 23.36 billion will be paid by the buyer. As part of consideration, KRW 23.36 billion is paid towards common equity of Samjin Pharmaceuticals Co., Ltd. The proceeds of the transaction will be used for securing funding for an investment. An undisclosed buyer completed the acquisition of 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) on May 19, 2026.New Risk • May 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).Buy Or Sell Opportunity • May 19Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to ₩24,700. The fair value is estimated to be ₩20,534, however this is not to be taken as a sell recommendation but rather should be used as a guide only.공고 • Feb 13Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 24, 2026Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: happy hall, 123, wausan-ro, mapo-gu, seoul South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 14 April 2026. Trailing yield: 3.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).Declared Dividend • Nov 08Dividend of ₩800 announcedDividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 14th April 2026 Dividend yield will be 4.0%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has not increased over the past 4 years but payments have been stable during that time.공고 • Nov 07Samjin Pharmaceuticals Co., Ltd. announces Annual dividend, payable on April 14, 2026Samjin Pharmaceuticals Co., Ltd. announced Annual dividend of KRW 800.0000 per share payable on April 14, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.5% to ₩16,990. The fair value is estimated to be ₩21,293, however this is not to be taken as a buy recommendation but rather should be used as a guide only.공고 • Feb 18Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 21, 2025Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 21, 2025, at 10:00 Tokyo Standard Time. Location: happy hall, 123, wausan-ro, mapo-gu, seoul South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).Declared Dividend • Nov 29Dividend of ₩800 announcedShareholders will receive a dividend of ₩800. Ex-date: 27th December 2024 Payment date: 15th April 2025 Dividend yield will be 4.3%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has not increased over the past 3 years but payments have been stable during that time.분석 기사 • Nov 21Estimating The Intrinsic Value Of Samjin Pharmaceuticals Co., Ltd. (KRX:005500)Key Insights The projected fair value for Samjin Pharmaceuticals is ₩21,186 based on Dividend Discount Model Samjin...Buy Or Sell Opportunity • Nov 14Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to ₩16,920. The fair value is estimated to be ₩21,186, however this is not to be taken as a buy recommendation but rather should be used as a guide only.공고 • Nov 13Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on May 12, 2025. As of November 12, 2024, the company had 1,372,620 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.공고 • Jun 05Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 2, 2024. As of June 2, 2024, the company had 1,125,036 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.New Risk • Mar 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Upcoming Dividend • Dec 20Upcoming dividend of ₩800 per share at 3.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).New Risk • Oct 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (7.7% increase in shares outstanding).공고 • Jun 17Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 15, 2023. As of June 15, 2023, the company had 897,920 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.Upcoming Dividend • Dec 21Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Trailing yield: 3.0%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).공고 • Dec 03Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on June 1, 2023. As of December 1, 2022, the company had 486,067 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Director Yong-Joo Choi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 19 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.0%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).Is New 90 Day High Low • Mar 04New 90-day low: ₩24,350The company is down 9.0% from its price of ₩26,850 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 18% over the same period.공고 • Feb 22Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 26, 2021Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.Is New 90 Day High Low • Jan 18New 90-day low: ₩25,550The company is down 7.0% from its price of ₩27,400 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.Upcoming Dividend • Dec 22Upcoming Dividend of ₩800 Per ShareWill be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in March 2011. The average dividend yield among industry peers is 0.6%.Is New 90 Day High Low • Oct 16New 90-day low: ₩27,200The company is down 1.0% from its price of ₩27,500 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.이익 및 매출 성장 예측KOSE:A005500 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028336,300N/A29,30045,000112/31/2027324,000N/A25,80041,100112/31/2026315,300N/A21,40036,300112/31/2025308,600N/A21,50017,700112/31/2024307,000N/A12,90016,900112/31/2022274,03221,894-18,20517,293N/A12/31/2021250,07028,404-50,25823,967N/A애널리스트 향후 성장 전망수입 대 저축률: A005500 의 예상 수익 증가율이 절약률(3.3%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: A005500 의 수익이 KR 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: A005500 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: A005500 의 수익(연간 3.1%)이 KR 시장(연간 14.3%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: A005500 의 수익(연간 3.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A005500의 자본 수익률은 3년 후 6.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/11 22:46종가2026/08/11 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Samjin Pharmaceuticals Co., Ltd.는 7명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hyuk Jin YoonEugene Investment & Securities Co Ltd.Jae Hoon ShinHanwha Investment & Securities Co., Ltd.Jong Kyung ChoiHeungkuk Securities Co., Ltd4명의 분석가 더 보기
Buy Or Sell Opportunity • Jul 29Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 9.4% to ₩16,960. The fair value is estimated to be ₩21,389, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
공고 • Jun 12An undisclosed buyer acquired 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) for KRW 23.4 billion.An undisclosed buyer agreed to acquire 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) for KRW 23.4 billion on May 14, 2026. A cash consideration of KRW 23.36 billion will be paid by the buyer. As part of consideration, KRW 23.36 billion is paid towards common equity of Samjin Pharmaceuticals Co., Ltd. The proceeds of the transaction will be used for securing funding for an investment. An undisclosed buyer completed the acquisition of 7.47% stake in Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) from Hana Pharm Co., Ltd. (KOSE:A293480) on May 19, 2026.
New Risk • May 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
Buy Or Sell Opportunity • May 19Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to ₩24,700. The fair value is estimated to be ₩20,534, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
공고 • Feb 13Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 24, 2026Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: happy hall, 123, wausan-ro, mapo-gu, seoul South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 14 April 2026. Trailing yield: 3.9%. Within top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.8%).
Declared Dividend • Nov 08Dividend of ₩800 announcedDividend of ₩800 is the same as last year. Ex-date: 29th December 2025 Payment date: 14th April 2026 Dividend yield will be 4.0%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has not increased over the past 4 years but payments have been stable during that time.
공고 • Nov 07Samjin Pharmaceuticals Co., Ltd. announces Annual dividend, payable on April 14, 2026Samjin Pharmaceuticals Co., Ltd. announced Annual dividend of KRW 800.0000 per share payable on April 14, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 5.5% to ₩16,990. The fair value is estimated to be ₩21,293, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
공고 • Feb 18Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 21, 2025Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 21, 2025, at 10:00 Tokyo Standard Time. Location: happy hall, 123, wausan-ro, mapo-gu, seoul South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 15 April 2025. Trailing yield: 4.4%. Within top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%).
Declared Dividend • Nov 29Dividend of ₩800 announcedShareholders will receive a dividend of ₩800. Ex-date: 27th December 2024 Payment date: 15th April 2025 Dividend yield will be 4.3%, which is higher than the industry average of 1.1%. Sustainability & Growth The dividend has not increased over the past 3 years but payments have been stable during that time.
분석 기사 • Nov 21Estimating The Intrinsic Value Of Samjin Pharmaceuticals Co., Ltd. (KRX:005500)Key Insights The projected fair value for Samjin Pharmaceuticals is ₩21,186 based on Dividend Discount Model Samjin...
Buy Or Sell Opportunity • Nov 14Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 11% to ₩16,920. The fair value is estimated to be ₩21,186, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
공고 • Nov 13Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on May 12, 2025. As of November 12, 2024, the company had 1,372,620 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
공고 • Jun 05Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 2, 2024. As of June 2, 2024, the company had 1,125,036 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
New Risk • Mar 16New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Upcoming Dividend • Dec 20Upcoming dividend of ₩800 per share at 3.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. Trailing yield: 3.7%. Within top quartile of South Korean dividend payers (3.5%). Higher than average of industry peers (1.1%).
New Risk • Oct 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (7.7% increase in shares outstanding).
공고 • Jun 17Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on December 15, 2023. As of June 15, 2023, the company had 897,920 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
Upcoming Dividend • Dec 21Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 18 April 2023. Trailing yield: 3.0%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%).
공고 • Dec 03Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces an Equity Buyback for KRW 5,000 million worth of its shares.Samjin Pharmaceuticals Co., Ltd. (KOSE:A005500) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust contract with Mirae Asset Securities Co., Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on June 1, 2023. As of December 1, 2022, the company had 486,067 shares in treasury within scope available for dividend and had 0 shares in treasury through other repurchase.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO & Director Yong-Joo Choi was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Dec 22Upcoming dividend of ₩800 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 19 April 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 3.0%. Within top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%).
Is New 90 Day High Low • Mar 04New 90-day low: ₩24,350The company is down 9.0% from its price of ₩26,850 on 04 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 18% over the same period.
공고 • Feb 22Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 26, 2021Samjin Pharmaceuticals Co., Ltd., Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time.
Is New 90 Day High Low • Jan 18New 90-day low: ₩25,550The company is down 7.0% from its price of ₩27,400 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 16% over the same period.
Upcoming Dividend • Dec 22Upcoming Dividend of ₩800 Per ShareWill be paid on the 13th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in March 2011. The average dividend yield among industry peers is 0.6%.
Is New 90 Day High Low • Oct 16New 90-day low: ₩27,200The company is down 1.0% from its price of ₩27,500 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.